Inflection Biosciences’ team brings considerable industry experience gained within large and small pharma, comprising expertise in small molecule drug development, intellectual property management, business development and fund raising.

Darren Cunningham, Co-Founder and Chief Executive Officer

Darren Cunningham has 20 years senior management experience in life science companies. Darren spent 8 years at Amarin Corporation plc in a range of senior positions with responsibility covering business and corporate development – comprising in-licensing, out-licensing, M&A, divestitures, deal negotiation; strategic planning, global intellectual property management, investor relations, fundraising, financial reporting and operations management. Prior to Amarin, Darren was an Associate Director of Strategic Planning at publicly quoted drug company Elan Corporation plc.

Darren holds a Bachelor of Commerce Degree from the National University of Ireland Galway, and a Masters in Accountancy from the Michael Smurfit Business School, University College Dublin. He trained at PricewaterhouseCoopers and is a Fellow of the Institute of Chartered Accountants in Ireland. He is also Adjunct Professor at the School of Biomolecular and Biomedical Science, University College Dublin.

Murray Yule M.D., Ph.D., Chief Medical Officer

Murray Yule is a board certified medical oncologist who trained in the United Kingdom and also at the MD Anderson Cancer Centre in Houston, Texas. He gained his PhD in anticancer therapeutics at the University of Newcastle and he is a member of the Royal College of Physicians of the UK. He has more than seventeen years’ experience in the Pharma Industry and has a broad experience of the development of early anticancer therapeutics having successfully filed multiple INDs and CTA applications exploring previously unrecognized cancer targets. In addition, Dr. Yule has published more than twenty papers in his career in the cancer space.

Whilst working at Eisai, Dr. Yule led the team that successfully achieved global market approval of eribulin for the treatment of metastatic breast cancer. As the Medical Director of Astex Therapeutics, he was instrumental in its merger with Supergen Inc. and ultimately its acquisition by Otsuka Pharmaceutical. As a former part of the BerGenBio ASA management team he contributed to its successful IPO on the Norwegian exchange in 2017. As a biotechnology medical officer Dr. Yule has successfully formed and driven translational and clinical collaborations with larger pharma including Novartis (small molecules leading to the development of ribociclib) and Merck (Immuno-oncology).

Shaun McNulty Ph.D., Chief Scientific Officer

Dr. Shaun McNulty is an experienced Chief Scientific Officer, with over 25 years of experience in the biotechnology and pharmaceutical sectors. Having obtained his doctorate in kinase-mediated signalling in glioma cells, from the University of York, Shaun undertook 5 years of post-doctoral study at the University of Cambridge, researching kinase-modulated signalling, transcription factor activation and protein expression. Shaun then held drug discovery leadership positions of increasing seniority for Pfizer and GSK, managing small molecule programmes into preclinical development and validating kinases as therapeutic targets. He worked on the Lyrica and Neurontin drug programmes and published more than thirty papers characterising signalling pathways.

Shaun moved into the Biotechnology sector in 2006, joining Syntaxin to direct their oncology discovery portfolio. He then moved to ImmBio, directing scientific collaborations and developing a fundraising strategy. As Biosceptre’s CSO since 2014, Shaun directed a portfolio of oncology candidates, obtaining regulatory approval for two candidates to enter the clinic. He is a member of the American Association for Cancer Research and the American Society of Clinical Oncology.

Tess Barker Ph.D., Head of Development 

Tess has nearly 20 years project management experience in the biotech/pharma industry. She has worked at companies including KS Biomedix, Microscience and Cambridge Antibody Technology before setting up her own consultancy business. Tess’ experience is focussed largely on the management of oncology projects as they progress through development into initial clinical studies, mostly with virtual or semi-virtual teams. Tess has a BSc in chemistry from the University of York and a PhD from the University of Birmingham.

Dr. Kathy Gately – Senior Scientist (Translational Oncology)

Dr Kathy Gately has 20 years of experience in the area of translational oncology research including biomarker discovery, cancer molecular diagnostics and pre-clinical drug testing. Her primary research focus is drug resistance mechanisms as novel biomarkers and targets for therapy. She is Clinical Senior Lecturer, Dept. of Clinical Medicine at the Trinity Translational Medicine Institute. Dr Gately’s group identified activated PIM kinase as a key mechanism of resistance to PI3K-mTOR inhibition in non-small cell lung cancer (NSCLC) and demonstrated that co-targeting PI3K and PIM kinase is a more effective treatment strategy than single targeted treatment. Further data from Dr. Gately’s group showed for the first time that PIM kinases are activated in two parallel mechanisms of resistance to EGFR TKIs (i) MET amplification and (ii) epithelial-to-mesenchymal transition (EMT).  Dr Gately is author or co-author of numerous publications relating to PI3K and PIM kinase.

Paul Dickinson BPharm (Hons) Ph.D. - CMC: Preclinical and Clinical Formulation Development

Paul was Senior Clinical Pharmacology Scientist at AstraZeneca and led the clinical pharmacology program to NDA/MAA for AZD9291/osimertinib, which had been awarded ‘breakthrough therapy’ status by the FDA.  Formerly Paul was a Principal Scientist within Pharmaceutical Development (AZ) leading both the global biopharmaceutics network and the Medicines Evaluation science community (USA, SE, UK). He is Director and co-founder of Seda Pharmaceutical Development Services, a company providing pharmaceutical development and clinical pharmacology services and consultancy to the Pharma Industry. 

Dr. David Lathbury – CMC: Process Chemistry

Dr Lathbury has over 25 years of industrial experience in the fine chemical, agrochemical, and pharmaceutical fields. Over the last 20 years he has worked in the pharmaceutical arena at SmithKline Beecham, and at AstraZeneca, where he was Head of Process Chemistry. Most recently he was Vice President of Chemical Development at Albany Molecular Research in Syracuse, New York. During his extensive career, David has worked on four marketed drugs, including process re-development activities on “Seroquel” and “Paxil”. During his time at AstraZeneca, his team was responsible for the chemical development of “Iressa” and “Crestor”. He is author or co-author on 30 publications and patents. David is a Fellow of the Royal Society of Chemistry and is a visiting Professor at Bristol University.

Frank Bonner – Head of Non-Clinical Safety

Frank has over 35 years of experience of toxicology and non-clinical drug development, gained in pharmaceutical (Senior Vice President, Sanofi), and contract research industries, and including 15 years as an independent consultant supporting the development of a diverse range of molecules. He has a comprehensive knowledge of non-clinical safety assessment including all aspects of regulatory guidance and advocacy, outsourced programme management, mechanistic toxicology and the application of new technologies to improve predictive screening.

He is a fellow of the British Toxicology Society, Past President of the Society and Visiting Professor in the Division of Integrative Systems Medicines at Imperial College, London. He has served as a Scientific Advisor for a number of technology and drug development SME’s and has Board level experience gained through various appointments including Executive Director, Stem Cells for Safer Medicines; Non-Executive Chairman, Maccine Pte, Singapore; Executive Director, Life Science Research Inc. etc.

Gerry McGettigan – Regulatory Affairs

Gerry, a molecular biologist, has twenty years’ experience in the biotechnology and pharmaceutical industries, in regulatory affairs, clinical development and business development. He has worked with large and medium pharma companies (Almirall and Glaxo) and was Regulatory & Scientific Affairs Director of cancer focused The Liposome Company, a US biotechnology firm. Gerry McGettigan is currently a Principal at Kinesys Consulting, a regulatory and technical advisory firm based in the U.K. Gerry holds a BSc, B.A. and is a fellow of Topra.

Gemma Carroll – Financial Controller

Experienced financial controller with extensive experience providing a broad range of financial management solutions for companies in a broad range of industry sectors, ranging from high potential start-ups, non-profit organisations and established small businesses to subsidiaries of multi-national companies.


Search - Use spaces to separate your keywords
Inflection Biosciences. Suite 15, Anglesea House Carysfort Avenue, Blackrock,  Co. Dublin.  

 Company registration no. 509046.

© 2020 Inflection Biosciences.   Web Design by Webtrade